Sugi Predict
/ Targets
/ XPOT
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to XPOT by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] |
PHASE3 | COMPLETED |
| Efficacy and Safety of XP12B in Women With Menorrhagia |
PHASE3 | COMPLETED |
| Safety Study of XP12B in Women With Menorrhagia |
PHASE3 | COMPLETED |
| Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma |
PHASE2 | RECRUITING |
| Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma |
PHASE1/PHASE2 | RECRUITING |
| Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study |
PHASE2 | RECRUITING |
| Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers |
PHASE1/PHASE2 | RECRUITING |
| A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Selinexor, Cyclophosphamide and Prednisone in Myeloma |
PHASE2 | COMPLETED |
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors |
PHASE2 | RECRUITING |
| A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL |
PHASE1/PHASE2 | RECRUITING |
| Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma |
PHASE2 | COMPLETED |
| Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes |
PHASE2 | COMPLETED |
| Avapritinib Maintenance for AML With KIT Mutations |
PHASE2 | NOT_YET_RECRUITING |
| Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma |
PHASE2 | NOT_YET_RECRUITING |
| Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients |
PHASE1/PHASE2 | UNKNOWN |
| A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) |
PHASE2 | COMPLETED |
| NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer |
PHASE1/PHASE2 | RECRUITING |
| Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Trial of Selinexor, Ruxolitinib and Methylprednisolone |
PHASE1 | RECRUITING |
| Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer |
PHASE1 | UNKNOWN |
| Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas |
PHASE1 | COMPLETED |
| Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML |
PHASE1 | COMPLETED |
| Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery |
PHASE1 | COMPLETED |
| A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes |
nan | COMPLETED |
| Treatment of Chronic Lymphocytic Leukemia |
nan | UNKNOWN |
| A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） |
nan | RECRUITING |
| Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma |
nan | ACTIVE_NOT_RECRUITING |
| Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a XPOT binder may also engage these)